Patents by Inventor Mark S. Jensen

Mark S. Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use
    Patent number: 8110569
    Abstract: Enantiomerically pure S-etifoxine and pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof are provided. Also provided are pharmaceutical compositions comprising the compounds and methods of treating disorders associated with central nervous system using the compounds and pharmaceutical compositions.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: February 7, 2012
    Assignee: The Regents of the University of California
    Inventors: David Putman, Derk Hogenkamp, Olivier Dasse, Edward R. Whittemore, Mark S. Jensen
  • Process for preparing sultams
    Publication number: 20040186093
    Abstract: The preparation of sultams is disclosed. In one embodiment (e.g. scheme (I)), an alkanesulfonyl halide is reacted with a haloalkylamine to obtain the corresponding N-(haloalkyl)alkanesulfonamide which is then cyclized in the presence of a deprotonating agent to give the sultam. The sultams are useful as intermediates in the preparation of naphthyridine carboxamide compounds which are HIV integrase inhibitors.
    Type: Application
    Filed: February 10, 2004
    Publication date: September 23, 2004
    Inventors: Jaemoon Lee, David Askin, Mark S Jensen, Yong-Li Zhong
  • Process and intermediates for the preparation of imidazolidinone &agr;v integrin antagonists
    Patent number: 6407241
    Abstract: A novel process is provided for the preparation of imidazolidinone &agr;v&bgr;3/&agr;v&bgr;5 integrin antagonists, and the useful intermediates obtained therein. These compounds are antagonists of &agr;v&bgr;3/&agr;v&bgr;5 integrin receptors and thus useful for inhibiting bone resorption and treating and preventing osteoporosis. Also disclosed is 3-{2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]imidazolidin-1-yl}-3(S)-(6-methoxy-pyridin-3-yl)-propionic acid in the form of a hemihydrate.
    Type: Grant
    Filed: November 7, 2000
    Date of Patent: June 18, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Mark S Jensen, Michael Palucki, Nelo R. Rivera, Kenneth M. Wells, Yi Xiao, Yaling Wang, Chunhua Yang, Nobuyoshi Yasuda
  • Crystalline 2-hydroxymethyl carbapenem intermediate compounds and process for synthesis thereof
    Patent number: 6346617
    Abstract: A process for preparation of a compound of formula I: wherein: R1 represents CH3 or H; and P represents a protecting group; comprising reacting a compound of formula IV:  wherein R1 and P and are defined above and R4 represents triflate or SO2F; in the presence of a catalyst and (R3)3SnCH2OP″, wherein each R3 represents C1-4 lower alkyl, and P″ represents H or a protecting group, to yield the compound of formula I.
    Type: Grant
    Filed: June 16, 1999
    Date of Patent: February 12, 2002
    Assignee: Merck & Co., Inc.
    Inventors: John Y. Chung, Nobuyoshi Yasuda, Johnnie L. Leazer, Jr., Mark S. Jensen, Kenneth M. Wells, Chunhua Yang
  • Process for the synthesis of carbapenem intermediated and compounds produced
    Patent number: 6235898
    Abstract: A process of synthesizing a carbapenem compound of formula 6: is disclosed using a compound of formula 4′: The intermediate compounds that are described herein are also included in the present invention.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: May 22, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark S. Jensen, Chunhua Yang, Nobuyoshi Yasuda
  • Process for synthesizing carbapenem intermediates
    Patent number: 6194568
    Abstract: The invention describes an improved process for synthesizing 1-&bgr;-methyl-2-hydroxymethyl substituted carbapenems as key intermediates for the synthesis of anti-MRSA carbapenem antibiotics. The synthesis eliminates the use of BU3SnCH2OH and HMPA, which are toxic substances and not amenable to industrial scale production. The novel intermediates are also within the scope of this invention. The invention relates to the synthesis of a compound of formula 3: wherein R1 represents H or a suitable protecting group for an alcohol; R2 represents H or methyl; and R5 represents a carboxy protecting group as well as the compounds made therein.
    Type: Grant
    Filed: June 4, 1999
    Date of Patent: February 27, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Mark S. Jensen, Yi Xiao, Chunhua Yang, Kenneth M. Wells, Nobuyoshi Yasuda
  • Process for the synthesis of 1-aza-5-halo-5-stannabicyclo[3.3.3]undecane carbapenem intermediates
    Patent number: 6069265
    Abstract: The present invention relates to a process for synthesizing novel intermediates of formula III: ##STR1## wherein R.sup.1 is a halogen. The intermediate compounds described herein are useful for the preparation of carbapenem compounds.
    Type: Grant
    Filed: August 19, 1999
    Date of Patent: May 30, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark S. Jensen, Chunhua Yang, Nobuyoshi Yasuda, David A. Colon, Yi Xiao
  • Process for the synthesis of carbapenem intermediates, and compounds produced
    Patent number: 6048978
    Abstract: A process of synthesizing a carbapenem compound of formula 6: ##STR1## is disclosed using a compound of formula 4': ##STR2## The intermediate compounds that are described herein are also included in the present invention.
    Type: Grant
    Filed: September 23, 1998
    Date of Patent: April 11, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Mark S. Jensen, Chunhua Yang, Nobuyoshi Yasuda